| P50 | author | Marco Blangetti | Q57056714 |
| P2093 | author name string | Cristina Prandi | |
| | Hinanit Koltai | |
| | Dvora Namdar | |
| P2860 | cites work | Chemical basis of hashish activity | Q93803717 |
| | The endocannabinoid system in normal and pathological brain ageing | Q22242668 |
| | Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects | Q24606148 |
| | Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials | Q24625489 |
| | Cannabinoids in health and disease | Q24633884 |
| | The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin | Q24643876 |
| | The orphan receptor GPR55 is a novel cannabinoid receptor | Q24670137 |
| | The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects | Q24681369 |
| | Amorfrutins are potent antidiabetic dietary natural products | Q27678567 |
| | Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets | Q28203208 |
| | Structure of a cannabinoid receptor and functional expression of the cloned cDNA | Q28240076 |
| | Molecular characterization of a peripheral receptor for cannabinoids | Q28298338 |
| | International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂ | Q28298445 |
| | International Union of Pharmacology. XXVII. Classification of cannabinoid receptors | Q29616832 |
| | Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. | Q33845285 |
| | Pharmacological characterization of GPR55, a putative cannabinoid receptor | Q33869340 |
| | Natural and synthetic endocannabinoids and their structure-activity relationships | Q33973921 |
| | Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients | Q33980833 |
| | Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside | Q34019573 |
| | The endocannabinoid system as a target for the treatment of neurodegenerative disease | Q34098196 |
| | Molecular probes for the cannabinoid receptors | Q34098959 |
| | Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy | Q34146329 |
| | TRPA1 mediates spinal antinociception induced by acetaminophen and the cannabinoid Δ(9)-tetrahydrocannabiorcol | Q34235326 |
| | Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study | Q34358022 |
| | Pharmacological treatment of Parkinson disease: a review | Q34416640 |
| | Evolution of the Cannabinoid and Terpene Content during the Growth of Cannabis sativa Plants from Different Chemotypes | Q34511965 |
| | CB2-selective cannabinoid receptor ligands: synthesis, pharmacological evaluation, and molecular modeling investigation of 1,8-Naphthyridin-2(1H)-one-3-carboxamides | Q34525138 |
| | Crystal Structure of the Human Cannabinoid Receptor CB1. | Q34543208 |
| | Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis | Q34561157 |
| | Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial | Q34638273 |
| | Medicinal chemistry endeavors around the phytocannabinoids | Q34666031 |
| | CB1 cannabinoid antagonists: structure-activity relationships and potential therapeutic applications | Q34752767 |
| | Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo | Q34804266 |
| | Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb | Q35001117 |
| | Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes | Q35035816 |
| | CB1 cannabinoid receptor signalling in Parkinson's disease | Q35054346 |
| | Endocannabinoid signaling and long-term synaptic plasticity. | Q35679432 |
| | Cannabinoids and glaucoma | Q35748271 |
| | Pharmacology of cannabinoids | Q35782063 |
| | The good and the bad effects of (-) trans-delta-9-tetrahydrocannabinol (Delta 9-THC) on humans | Q35859623 |
| | Natural cannabinoids: templates for drug discovery | Q36293580 |
| | Plant, synthetic, and endogenous cannabinoids in medicine | Q36366922 |
| | Investigations on the 4-quinolone-3-carboxylic acid motif part 5: modulation of the physicochemical profile of a set of potent and selective cannabinoid-2 receptor ligands through a bioisosteric approach. | Q36452404 |
| | Low-dose vaporized cannabis significantly improves neuropathic pain | Q36593518 |
| | Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis | Q36848624 |
| | The Structure-Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation. | Q37052244 |
| | A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain | Q37141496 |
| | The 2-alkyl-2H-indazole regioisomers of synthetic cannabinoids AB-CHMINACA, AB-FUBINACA, AB-PINACA, and 5F-AB-PINACA are possible manufacturing impurities with cannabimimetic activities | Q37146954 |
| | Targeting the endocannabinoid system: to enhance or reduce? | Q37150745 |
| | Structure determination and absolute configuration of cannabichromanone derivatives from high potency Cannabis sativa | Q37390519 |
| | Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease | Q37553341 |
| | Prospects for cannabinoid therapies in basal ganglia disorders | Q37872326 |
| | Phytocannabinoids as novel therapeutic agents in CNS disorders. | Q37933589 |
| | Endogenous cannabinoids revisited: a biochemistry perspective. | Q38087791 |
| | Amorfrutins: A promising class of natural products that are beneficial to health | Q38217801 |
| | Endocannabinoids and Their Pharmacological Actions | Q38593112 |
| | GPR55 - a putative "type 3" cannabinoid receptor in inflammation | Q38669741 |
| | Medicinal Chemistry, Pharmacology, and Potential Therapeutic Benefits of Cannabinoid CB2 Receptor Agonists | Q38689260 |
| | New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity | Q38879833 |
| | Advances in the Physiology of GPR55 in the Central Nervous System | Q38917434 |
| | Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists. | Q38935374 |
| | Phytocannabinoids: a unified critical inventory | Q38976904 |
| | Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors | Q39255628 |
| | Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: an investigation of the 1,8-naphthyridin-2(1H)-one scaffold. | Q39368198 |
| | Perspectives of Cannabinoid Type 2 Receptor (CB2R) Ligands in Neurodegenerative Disorders: Structure-Affinity Relationship (SAfiR) and Structure-Activity Relationship (SAR) Studies | Q39368926 |
| | Structure-activity relationships in cannabinoids | Q39504398 |
| | Imidazopyridine CB2 agonists: optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy | Q39975832 |
| | Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity. | Q40075003 |
| | Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models | Q42508054 |
| | Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice | Q42731656 |
| | Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease | Q43504648 |
| | Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. | Q43641975 |
| | Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study | Q43820144 |
| | The structure of cannabitriol | Q43974227 |
| | Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor | Q44303656 |
| | Antimicrobial and antiparasitic (+)-trans-hexahydrodibenzopyrans and analogues from Machaerium multiflorum | Q44492635 |
| | 6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist | Q44806888 |
| | Manipulation of the tetrahydrocannabinol side chain delineates agonists, partial agonists, and antagonists | Q44863367 |
| | Selective cannabinoid receptor type 2 (CB2) agonists: optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain | Q45004592 |
| | High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. | Q46456086 |
| | Early medical use of cannabis | Q47261270 |
| | Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease | Q48235219 |
| | Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPARγ receptor | Q49433973 |
| | Synthesis and pharmacological evaluation of new biphenylic derivatives as CB2 receptor ligands. | Q50861387 |
| | Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor. | Q51744729 |
| | Amorfrutins Are Natural PPARγ Agonists with Potent Anti-inflammatory Properties. | Q52867069 |
| | Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds. | Q53242382 |
| | Sequence heterogeneity of cannabidiolic- and tetrahydrocannabinolic acid-synthase in Cannabis sativa L. and its relationship with chemical phenotype | Q56969165 |
| | Synthesis, biological activity and molecular modeling of new biphenylic carboxamides as potent and selective CB2 receptor ligands | Q58855665 |
| | 1,2-Dihydro-2-oxopyridine-3-carboxamides: The C-5 substituent is responsible for functionality switch at CB2 cannabinoid receptor | Q59033475 |
| | Benzimidazole CB2 agonists: Design, synthesis and SAR | Q60682456 |
| | [Cannabinoid system and neuroinflammation:therapeutic perspectives in multiple sclerosis] | Q60696495 |
| | Acute effects of smoked marijuana and oral delta9-tetrahydrocannabinol on specific airway conductance in asthmatic subjects | Q69742476 |
| | Hashish. IV. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids | Q72692479 |
| | Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? | Q81059625 |
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P433 | issue | 7 | |
| P921 | main subject | Cannabis | Q79817 |
| P577 | publication date | 2018-06-25 | |
| P1433 | published in | Molecules | Q151332 |
| P1476 | title | Structure-Activity Relationship of Cannabis Derived Compounds for the Treatment of Neuronal Activity-Related Diseases | |
| P478 | volume | 23 | |